MX349827B - Compuestos que contienen nitrogeno y su uso. - Google Patents

Compuestos que contienen nitrogeno y su uso.

Info

Publication number
MX349827B
MX349827B MX2013015079A MX2013015079A MX349827B MX 349827 B MX349827 B MX 349827B MX 2013015079 A MX2013015079 A MX 2013015079A MX 2013015079 A MX2013015079 A MX 2013015079A MX 349827 B MX349827 B MX 349827B
Authority
MX
Mexico
Prior art keywords
containing compounds
nitrogen containing
compounds
preventing
formula
Prior art date
Application number
MX2013015079A
Other languages
English (en)
Other versions
MX2013015079A (es
Inventor
Bhagwat Sachin
Jagdishwar Patil Vijaykumar
Tadiparthi Ravikumar
Birajdar Satish
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2013015079A publication Critical patent/MX2013015079A/es
Publication of MX349827B publication Critical patent/MX349827B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la fórmula (I): (ver Fórmula) su preparación y su uso en la prevención o el tratamiento de infecciones bacterianas.
MX2013015079A 2011-09-13 2012-09-11 Compuestos que contienen nitrogeno y su uso. MX349827B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2582MU2011 2011-09-13
PCT/IB2012/054706 WO2013038330A1 (en) 2011-09-13 2012-09-11 Nitrogen containing compounds and their use

Publications (2)

Publication Number Publication Date
MX2013015079A MX2013015079A (es) 2014-01-24
MX349827B true MX349827B (es) 2017-08-14

Family

ID=47116128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015079A MX349827B (es) 2011-09-13 2012-09-11 Compuestos que contienen nitrogeno y su uso.

Country Status (13)

Country Link
US (3) US8754102B2 (es)
EP (1) EP3052497B1 (es)
JP (2) JP6114275B2 (es)
KR (1) KR101680933B1 (es)
CN (1) CN103781787B (es)
AU (1) AU2012310136B2 (es)
BR (1) BR112014003476A2 (es)
CA (1) CA2846107C (es)
ES (1) ES2640520T3 (es)
MX (1) MX349827B (es)
RU (1) RU2569307C1 (es)
WO (1) WO2013038330A1 (es)
ZA (1) ZA201308930B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754102B2 (en) * 2011-09-13 2014-06-17 Wockhardt Ltd. Nitrogen containing compounds and their use
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2831069B1 (en) 2012-03-30 2017-07-12 Merck Sharp & Dohme Corp. Isoxazole beta-lactamase inhibitors
AU2013237939A1 (en) 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
PT2857401T (pt) 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
US20150315145A1 (en) * 2012-11-01 2015-11-05 Kaneka Corporation Process for producing optically active bicyclic urea compound
CA2904084C (en) * 2013-03-08 2017-03-28 Wockhardt Limited A process for preparation of (2s, 5r)- sulfuric acid mono-{[(4-aminopiperidin-4-yl) carbonyl]-7-oxo-1,6-diaza-bicyclo[3.2.1]-oct-6-yl} ester
JP6253676B2 (ja) * 2013-03-08 2017-12-27 ウォックハート リミテッド （２ｓ，５ｒ）−２−カルボキシアミド−７−オキソ−６−スルホオキシ−１，６−ジアザ−ビシクロ［３．２．１］オクタンのナトリウム塩のためのプロセス
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
WO2015046207A1 (ja) 2013-09-24 2015-04-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ジアザビシクロオクタン誘導体の製造法とその中間体
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
SG11201602723RA (en) 2013-10-08 2016-05-30 Meiji Seika Pharma Co Ltd Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
CA2926773A1 (en) * 2013-10-11 2015-04-16 Wockhardt Limited Nitrogen containing compounds and their use
IN2013MU03308A (es) 2013-10-22 2015-07-17 Wockhardt Ltd
US9663518B1 (en) 2014-02-03 2017-05-30 Wockhardt Limited Process for preparation of (2S, 5R)-1,6-diaza-bicyclo[3.2.1]octane-2-carbonitrile-7-oxo-6-(sulfooxy)-mono sodium salt
US20170065566A1 (en) * 2014-02-20 2017-03-09 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
KR20160126004A (ko) * 2014-03-14 2016-11-01 욱크하르트 리미티드 항세균제를 포함하는 제약학적 조성물
EP3122745B1 (en) 2014-03-24 2019-02-27 Novartis AG Monobactam organic compounds for the treatment of bacterial infections
US9688677B1 (en) 2014-03-29 2017-06-27 Wockhardt Limited Process for preparation of sodium (2S, 5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate
EP3131555A1 (en) * 2014-04-18 2017-02-22 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
EP3131583A1 (en) * 2014-04-18 2017-02-22 The Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
WO2016081452A1 (en) 2014-11-17 2016-05-26 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
RU2732129C2 (ru) 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
JP2018530553A (ja) 2015-10-02 2018-10-18 レゴケム バイオサイエンシズ， インク．Ｌｅｇｏｃｈｅｍ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． β−ラクタマーゼを阻害するための組成物及び方法
CN106749242B (zh) * 2015-11-23 2021-04-02 上海医药工业研究院 阿维巴坦中间体的制备方法
US10800778B2 (en) 2016-09-16 2020-10-13 Entasis Therapeutics Limited Beta-lactamase inhibitor compounds
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
JP2020506198A (ja) * 2017-02-06 2020-02-27 ミュタビリスＭｕｔａｂｉｌｉｓ 新規な複素環化合物と、細菌感染症の予防または治療におけるその利用
WO2018193368A1 (en) * 2017-04-18 2018-10-25 Wockhardt Limited Antibacterial compositions
LT3630111T (lt) 2017-05-08 2022-03-10 Entasis Therapeutics, Inc. Junginiai ir būdai, skirti bakterinių infekcijų gydymui
AU2018304907B2 (en) 2017-07-21 2022-11-24 Antabio Sas Chemical compounds
CN109400521B (zh) * 2017-08-18 2020-05-08 新发药业有限公司 一种改进的5r-苄氧氨基哌啶-2s-甲酸酯、其草酸盐的制备方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109870583B (zh) * 2019-04-15 2020-03-06 德阳市人民医院 急性胰腺炎相关的代谢物及其应用
WO2021165927A1 (en) 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177099T1 (de) * 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
EP3260551A1 (en) * 2008-06-19 2017-12-27 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1] octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
US8754102B2 (en) * 2011-09-13 2014-06-17 Wockhardt Ltd. Nitrogen containing compounds and their use

Also Published As

Publication number Publication date
US8754102B2 (en) 2014-06-17
JP2014521739A (ja) 2014-08-28
US20140088070A1 (en) 2014-03-27
EP3052497B1 (en) 2017-06-28
BR112014003476A2 (pt) 2017-03-01
KR101680933B1 (ko) 2016-11-29
RU2014109447A (ru) 2015-11-10
US20150141394A1 (en) 2015-05-21
JP2016047853A (ja) 2016-04-07
RU2569307C1 (ru) 2015-11-20
CA2846107C (en) 2016-06-21
ZA201308930B (en) 2015-02-25
EP3052497A1 (en) 2016-08-10
AU2012310136A1 (en) 2013-12-19
AU2012310136B2 (en) 2016-07-07
CN103781787A (zh) 2014-05-07
NZ618286A (en) 2015-07-31
WO2013038330A1 (en) 2013-03-21
KR20140023401A (ko) 2014-02-26
US9090616B2 (en) 2015-07-28
US8969334B2 (en) 2015-03-03
MX2013015079A (es) 2014-01-24
JP6114275B2 (ja) 2017-04-12
CN103781787B (zh) 2015-09-23
US20150018312A1 (en) 2015-01-15
CA2846107A1 (en) 2013-03-21
ES2640520T3 (es) 2017-11-03

Similar Documents

Publication Publication Date Title
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
MX2012010671A (es) Compuestos antiinfecciosos.
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MY177344A (en) Compounds and their methods of use
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MY173518A (en) Antimicrobial compounds and methods of making and using the same
PH12015501609A1 (en) Phenicol antibacterials
PH12015501088A1 (en) Dimeric compounds
MX2016009248A (es) Compuestos que contienen nitrogeno y su uso como agentes antibacterianos.
MX354988B (es) Formulaciones de anticuerpo y metodos.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
MX336294B (es) Inhibidores de iap.
SG10201900541QA (en) Derivatives of xanthone compounds
MX2014006686A (es) Derivaods novedosos de pirrol.
MX2015005753A (es) Agentes antimicrobianos.
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
PH12015500399A1 (en) Azaindolines
PH12015500185B1 (en) Azaheterocycles as bir2 and/or bir3 inhibitors
IN2013MU03216A (es)
MX357352B (es) Uso de derivados poliaminoisoprenilo en un tratamiento antibiotico o antiseptico.
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.
IN2015DN02109A (es)

Legal Events

Date Code Title Description
FG Grant or registration